PMID- 37488926
OWN - NLM
STAT- Publisher
LR  - 20231013
IS  - 2383-5001 (Electronic)
IS  - 2288-8128 (Print)
IS  - 2288-8128 (Linking)
VI  - 23
IP  - 2
DP  - 2023 Sep
TI  - Feasibility of additional radiotherapy in patients with advanced hepatocellular 
      carcinoma treated with atezolizumab plus bevacizumab.
PG  - 330-340
LID - 10.17998/jlc.2023.04.14 [doi]
AB  - BACKGROUND/AIM: Radiotherapy (RT) is an effective local treatment for 
      hepatocellular carcinoma (HCC). However, whether additional RT is safe and 
      effective in patients with advanced HCC receiving atezolizumab plus bevacizumab 
      remains unclear. This retrospective cohort study aimed to evaluate the 
      feasibility of additional RT in these patients. METHODS: Between March and 
      October 2021, we retrospectively analyzed seven patients with advanced HCC who 
      received RT during treatment with atezolizumab plus bevacizumab. The median 
      prescribed RT dose was 35 Gy (range, 33-66). Freedom from local progression 
      (FFLP), progression-free survival (PFS), and overall survival (OS) after RT were 
      analyzed. RESULTS: The median follow-up duration after RT was 14.2 months (range, 
      10.0-18.6). Of the seven patients, disease progression was noted in six (85.7%), 
      the sites of disease progression were local in two (28.6%), intrahepatic in four 
      (57.1%), and extrahepatic in four (57.1%). The median time of FFLP was not 
      reached, and PFS and OS times were 4.0 (95% confidence interval [CI], 3.6-4.5) 
      and 14.8% (95% CI, 12.5-17.2) months, respectively. The 1-year FFLP, PFS, and OS 
      rates were 60% (95% CI, 43.8-76.2), 0%, and 85.7% (95% CI, 75.9-95.5), 
      respectively. Grade 3 or higher hematologic adverse events (AEs) were not 
      observed, but grade 3 nonhematologic AEs unrelated to RT were observed in one 
      patient. CONCLUSIONS: The addition of RT may be feasible in patients with 
      advanced HCC treated with atezolizumab plus bevacizumab. However, further studies 
      are required to validate these findings.
FAU - Kim, Tae Hyun
AU  - Kim TH
AD  - Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, 
      Korea.
AD  - Proton Therapy Center, National Cancer Center, Goyang, Korea.
FAU - Kim, Bo Hyun
AU  - Kim BH
AD  - Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, 
      Korea.
FAU - Cho, Yu Ri
AU  - Cho YR
AD  - Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, 
      Korea.
FAU - Koh, Young-Hwan
AU  - Koh YH
AD  - Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, 
      Korea.
FAU - Park, Joong-Won
AU  - Park JW
AD  - Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, 
      Korea.
LA  - eng
GR  - NCC2110351/National Cancer Center/Republic of Korea
GR  - Korean Liver Cancer Association/
PT  - Journal Article
DEP - 20230516
PL  - Korea (South)
TA  - J Liver Cancer
JT  - Journal of liver cancer
JID - 101650610
PMC - PMC10565546
OTO - NOTNLM
OT  - Atezolizumab
OT  - Bevacizumab
OT  - Carcinoma, hepatocellular
OT  - Radiotherapy
OT  - Survival
COIS- Conflict of Interest The authors have no conflicts of interest to disclose.
EDAT- 2023/07/25 06:42
MHDA- 2023/07/25 06:42
PMCR- 2023/09/01
CRDT- 2023/07/25 01:33
PHST- 2023/03/20 00:00 [received]
PHST- 2023/04/14 00:00 [accepted]
PHST- 2023/07/25 06:42 [pubmed]
PHST- 2023/07/25 06:42 [medline]
PHST- 2023/07/25 01:33 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - jlc.2023.04.14 [pii]
AID - jlc-2023-04-14 [pii]
AID - 10.17998/jlc.2023.04.14 [doi]
PST - ppublish
SO  - J Liver Cancer. 2023 Sep;23(2):330-340. doi: 10.17998/jlc.2023.04.14. Epub 2023 
      May 16.